Cargando…

Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells: An Eotaxin and STAT6-dependent Process

Currently most attempts at cancer immunotherapy involve the generation of CD8(+) cytotoxic T lymphocytes (CTLs) against tumor-associated antigens. Many tumors, however, have been immunoselected to evade recognition by CTLs and thus alternative approaches to cancer immunotherapy are urgently needed....

Descripción completa

Detalles Bibliográficos
Autores principales: Mattes, Joerg, Hulett, Mark, Xie, Wei, Hogan, Simon, Rothenberg, Marc E., Foster, Paul, Parish, Christopher
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193835/
https://www.ncbi.nlm.nih.gov/pubmed/12566422
http://dx.doi.org/10.1084/jem.20021683
_version_ 1782147563375296512
author Mattes, Joerg
Hulett, Mark
Xie, Wei
Hogan, Simon
Rothenberg, Marc E.
Foster, Paul
Parish, Christopher
author_facet Mattes, Joerg
Hulett, Mark
Xie, Wei
Hogan, Simon
Rothenberg, Marc E.
Foster, Paul
Parish, Christopher
author_sort Mattes, Joerg
collection PubMed
description Currently most attempts at cancer immunotherapy involve the generation of CD8(+) cytotoxic T lymphocytes (CTLs) against tumor-associated antigens. Many tumors, however, have been immunoselected to evade recognition by CTLs and thus alternative approaches to cancer immunotherapy are urgently needed. Here we demonstrate that CD4(+) T cells that recognize a secreted tumor-specific antigen and exhibit a cytokine secretion profile characteristic of Th2 cells, are capable of clearing established lung and visceral metastases of a CTL-resistant melanoma. Clearance of lung metastases by the Th2 cells was found to be totally dependent on the eosinophil chemokine, eotaxin, and partially dependent on the transcription activator signal transducer and activator of transcription 6 (STAT6), with degranulating eosinophils within the tumors inducing tumor regression. In contrast, tumor-specific CD4(+) Th1 cells, that recruited macrophages into the tumors, had no effect on tumor growth. This work provides the basis for a new approach to adoptive T cell immunotherapy of cancer.
format Text
id pubmed-2193835
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-21938352008-04-11 Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells: An Eotaxin and STAT6-dependent Process Mattes, Joerg Hulett, Mark Xie, Wei Hogan, Simon Rothenberg, Marc E. Foster, Paul Parish, Christopher J Exp Med Brief Definitive Report Currently most attempts at cancer immunotherapy involve the generation of CD8(+) cytotoxic T lymphocytes (CTLs) against tumor-associated antigens. Many tumors, however, have been immunoselected to evade recognition by CTLs and thus alternative approaches to cancer immunotherapy are urgently needed. Here we demonstrate that CD4(+) T cells that recognize a secreted tumor-specific antigen and exhibit a cytokine secretion profile characteristic of Th2 cells, are capable of clearing established lung and visceral metastases of a CTL-resistant melanoma. Clearance of lung metastases by the Th2 cells was found to be totally dependent on the eosinophil chemokine, eotaxin, and partially dependent on the transcription activator signal transducer and activator of transcription 6 (STAT6), with degranulating eosinophils within the tumors inducing tumor regression. In contrast, tumor-specific CD4(+) Th1 cells, that recruited macrophages into the tumors, had no effect on tumor growth. This work provides the basis for a new approach to adoptive T cell immunotherapy of cancer. The Rockefeller University Press 2003-02-03 /pmc/articles/PMC2193835/ /pubmed/12566422 http://dx.doi.org/10.1084/jem.20021683 Text en Copyright © 2003, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Brief Definitive Report
Mattes, Joerg
Hulett, Mark
Xie, Wei
Hogan, Simon
Rothenberg, Marc E.
Foster, Paul
Parish, Christopher
Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells: An Eotaxin and STAT6-dependent Process
title Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells: An Eotaxin and STAT6-dependent Process
title_full Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells: An Eotaxin and STAT6-dependent Process
title_fullStr Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells: An Eotaxin and STAT6-dependent Process
title_full_unstemmed Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells: An Eotaxin and STAT6-dependent Process
title_short Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells: An Eotaxin and STAT6-dependent Process
title_sort immunotherapy of cytotoxic t cell–resistant tumors by t helper 2 cells: an eotaxin and stat6-dependent process
topic Brief Definitive Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193835/
https://www.ncbi.nlm.nih.gov/pubmed/12566422
http://dx.doi.org/10.1084/jem.20021683
work_keys_str_mv AT mattesjoerg immunotherapyofcytotoxictcellresistanttumorsbythelper2cellsaneotaxinandstat6dependentprocess
AT hulettmark immunotherapyofcytotoxictcellresistanttumorsbythelper2cellsaneotaxinandstat6dependentprocess
AT xiewei immunotherapyofcytotoxictcellresistanttumorsbythelper2cellsaneotaxinandstat6dependentprocess
AT hogansimon immunotherapyofcytotoxictcellresistanttumorsbythelper2cellsaneotaxinandstat6dependentprocess
AT rothenbergmarce immunotherapyofcytotoxictcellresistanttumorsbythelper2cellsaneotaxinandstat6dependentprocess
AT fosterpaul immunotherapyofcytotoxictcellresistanttumorsbythelper2cellsaneotaxinandstat6dependentprocess
AT parishchristopher immunotherapyofcytotoxictcellresistanttumorsbythelper2cellsaneotaxinandstat6dependentprocess